ClinicalTrials.gg

How we know

Every link on this study, and who decided it

The study on the left, the conditions and drugs this site links it to, and on each link the judgments that made or checked it, by day and by judge. The top row is the record itself: each new version seen since tracking began. Dashed lines are links the registry record does not make itself. Select a link to see everything judged on it, or a mark for one decision with its reason and evidence.

5 links2 made here, not in the record6 judgments2 judges (the rules as one: Rule based)1 record change seen
Claude Opus 5.5Rule basedRecord updated on ClinicalTrials.govMade here
Oct 19Oct 26Nov 2Nov 9Nov 16TodayNCT07935928A Multicenter StudyEvaluating the Efficacy andSafety of Nivolumab andIpilimumab in CombinationWith NP-101 Versus Placeboin Refractory Advanced andMetastaticNovatek PharmaceuticalsPhase 2/Phase 3 · not yet recrRECORDThe record itselfVersions seen nightly since Sep 25, 2…›Nov 13 · ClinicalTrials.gov record · Version of 2026-11-13Version of 2026-11-13CONDITIONSGastro-enteropancreatic neu…No longer in the registry's filing›Nov 14 · Rule based · Finest filed termAs of now · Rule based · Main conditionMain conditionDRUGSNigella sativa oilEntry “NP-101”, read by our name rule›Nov 18 · Rule based · TestedTestedBlack Seed Oil Extract Supp…Entry “NP-101”, read by our name rule›Nov 18 · Rule based · TestedTestedNivolumabMade here · Found by reading; no entr…›Nov 16 · Claude Opus 5.5 · Background · partnerBackground · partnerIpilimumabMade here · Found by reading; no entr…›Nov 16 · Claude Opus 5.5 · Background · partnerBackground · partner

Times are in your time zone; a day marked “day only” kept no time. The graph scrolls sideways on a narrow screen; every mark is also in the list below.

Nivolumab

Made here1 judgment on this link
NCT07935928gives it, found by reading the recordNivolumabDefined by Claude Opus 5.5Nov 16 (day only)
Role in the study, from the registry to what was judged
RegistryNot in the recordno intervention entry names it
→judged

All judgments on this study

WhenLinkJudgeDecisionState
Nov 13The record itselfClinicalTrials.gov recordVersion of 2026-11-13Record change
Nov 14Gastro-enteropancreatic neuroendocrine tumorRule based · condition-kind ruleFinest filed termCurrent
Nov 16Nivolumabmade hereClaude Opus 5.5Background · partnerCurrent
Nov 16Ipilimumabmade hereClaude Opus 5.5Background · partnerCurrent
Nov 18Nigella sativa oilRule based · role ruleTestedCurrent
Nov 18Black Seed Oil Extract SupplementRule based · role ruleTestedCurrent
As of nowGastro-enteropancreatic neuroendocrine tumorRule based · main-condition ruleMain conditionCurrent

The rules, in plain words

“Rule based” means one of these decided, not a model or a person. Each runs every night over every study.

Which drugs a study tests

Reads each treatment the study lists and the arms it is in. A drug only in the experimental arm is tested. A drug in every arm while something else changes between the arms is given beside it. A drug only in the control arm is the comparator. Placebo, procedures and usual care are known by name.

Where the whole record has been read, that reading's answer replaces the rule's.

What a study is mainly about

Starts from the first condition ClinicalTrials.gov files the study under. It moves to a narrower one only when the study's own title or listed conditions name it, and sets aside terms the registry often files by mistake. A study open to many cancers is not placed under one of them unless its title names it.

Checked against studies judged one by one; the study page says when it differs from the registry.

How a condition link is counted

For each condition a study is filed under: whether it is the study's own condition at the finest the study states it, a wider one, a general category, or filed by mistake; and whether it is the main condition, a setting the study names, or only how it was filed.

A decision on file for one study overrides it, with who made it and when.